HQL Stock Overview
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Abrdn Life Sciences Investors Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.15 |
| 52 Week High | US$14.37 |
| 52 Week Low | US$11.34 |
| Beta | 0.72 |
| 1 Month Change | -2.95% |
| 3 Month Change | -4.78% |
| 1 Year Change | -5.26% |
| 3 Year Change | -36.69% |
| 5 Year Change | -19.91% |
| Change since IPO | -12.33% |
Recent News & Updates
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
Sep 27HQL: 13% Discount Creates An Opportunity
Jun 29Recent updates
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
Sep 27HQL: 13% Discount Creates An Opportunity
Jun 29Tekla Life Sciences raises dividend by 6.5% to $0.33
Feb 15Tekla Life Sciences declines quarterly dividend by -11.4% to $0.31/share
Nov 16Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
Oct 23HQL: A Biotechnology Equity CEF With No Leverage
Jul 12HQL: Buy For The Yield, If You Can Stomach The Depreciation
Apr 27Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend
Feb 11Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income
Sep 22Evaluating Closed-End Funds: HQL Is Another Fine Pick In A Hot Sector
Jun 29Tekla Life Sciences Investors: 8% Yield, 7% Discount
Jan 09Tekla Life Sciences declares $0.02 special dividend
Dec 21Tekla Life Sciences declares $0.40 dividend
Nov 16Shareholder Returns
| HQL | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | 2.6% | -0.7% | -3.2% |
| 1Y | -5.3% | 23.2% | 19.3% |
Return vs Industry: HQL underperformed the US Capital Markets industry which returned 23.2% over the past year.
Return vs Market: HQL underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| HQL volatility | |
|---|---|
| HQL Average Weekly Movement | 2.1% |
| Capital Markets Industry Average Movement | 3.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HQL has not had significant price volatility in the past 3 months.
Volatility Over Time: HQL's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | n/a | Dan Omstead | n/a |
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies.
Abrdn Life Sciences Investors Fundamentals Summary
| HQL fundamental statistics | |
|---|---|
| Market cap | US$348.02m |
| Earnings (TTM) | US$5.50m |
| Revenue (TTM) | US$3.51m |
64.1x
P/E Ratio100.3x
P/S RatioIs HQL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HQL income statement (TTM) | |
|---|---|
| Revenue | US$3.51m |
| Cost of Revenue | US$0 |
| Gross Profit | US$3.51m |
| Other Expenses | -US$1.98m |
| Earnings | US$5.50m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 100.00% |
| Net Profit Margin | 156.45% |
| Debt/Equity Ratio | 2.2% |
How did HQL perform over the long term?
See historical performance and comparison